secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-059740
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic earns $2.5M milestone payment from Roche for IBD program
-----------------------------------------------------------------

- Third milestone achieved under June 2021 Roche collaboration for Synthetic Biotic in IBD.
- $2.5 million payment triggered; previous milestones in Sep 2021 and Aug 2022.
- Roche retains exclusive option to license and commercialize the candidate.
- Synlogic's Synthetic Biotics are oral, gut-restricted biotherapeutics for serious diseases.
- Mylene Perreault, VP Research, emphasizes compelling fit with IBD disease biology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/0000950170-23-059740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/sybx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer